AZD3480 misses AD endpoint

Targacept (NASDAQ:TRGT) and AstraZeneca (LSE:AZN; NYSE:AZN) said top-line data from the Phase IIb Sirocco trial to treat mild to moderate Alzheimer's disease (AD) showed all three doses of AZD3480 ( TC-1734) and the active-control, donepezil, missed the primary endpoint of change from baseline on ADAS-Cog at 12 weeks. The companies said the results were "inconclusive" because of an improvement in the placebo group. The double-blind, international study in 567 patients evaluated 5, 20 and 100 mg doses of AZD3480. ...